Literature DB >> 11425946

Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients.

M A Dalal1, A Schuld, M Haack, M Uhr, P Geisler, I Eisensehr, S Noachtar, T Pollmächer.   

Abstract

Deficient orexin signaling has been shown to cause narcolepsy-like conditions in animals. In human narcolepsy, CSF levels of orexin A (hypocretin-1) were reported to be low in most cases. The authors measured CSF and plasma orexin A levels in patients with narcolepsy and in controls. Confirming earlier studies, they found CSF orexin A levels to be extremely low in patients with narcolepsy. However, plasma orexin A levels did not differ from those observed in controls. These results suggest that orexin deficiency in patients with narcolepsy is a phenomena restricted to the CNS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425946     DOI: 10.1212/wnl.56.12.1749

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  [The neurotransmitter, hypocretin. An overview].

Authors:  C Baumann; C Bassetti
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

Review 2.  [The neurophysiology of cataplexy].

Authors:  G Mayer
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

3.  Narcolepsy and the T-cell receptor.

Authors:  Timothy J Vyse
Journal:  Nat Genet       Date:  2009-06       Impact factor: 38.330

Review 4.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia.

Authors:  C Liguori; A Romigi; N B Mercuri; M Nuccetelli; F Izzi; M Albanese; G Sancesario; A Martorana; G M Sancesario; S Bernardini; M G Marciani; F Placidi
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

6.  Glucose tolerance in patients with narcolepsy.

Authors:  Pierre A Beitinger; Stephany Fulda; Mira A Dalal; Renate Wehrle; Marietta Keckeis; Thomas C Wetter; Fang Han; Thomas Pollmächer; Andreas Schuld
Journal:  Sleep       Date:  2012-02-01       Impact factor: 5.849

7.  Associations of plasma hypocretin-1 with metabolic and reproductive health: Two systematic reviews of clinical studies.

Authors:  Galit L Dunietz; Giancarlo Vanini; Carol Shannon; Louise M O'Brien; Ronald D Chervin
Journal:  Sleep Med Rev       Date:  2020-03-17       Impact factor: 11.609

8.  Sympathetic nerve activity and neuro-inflammation: Who is in the driver's seat?

Authors:  S Mukerjee; E Lazartigues
Journal:  Acta Physiol (Oxf)       Date:  2017-12-20       Impact factor: 6.311

Review 9.  Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation.

Authors:  Kevin G Burfeind; Vijayshree Yadav; Daniel L Marks
Journal:  Curr Neurol Neurosci Rep       Date:  2016-11       Impact factor: 5.081

10.  CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions.

Authors:  Y Dauvilliers; C R Baumann; B Carlander; M Bischof; T Blatter; M Lecendreux; F Maly; A Besset; J Touchon; M Billiard; M Tafti; C L Bassetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.